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Expression quantitative trait locusa b s t r a c t
Genes in the HLA class II region include the most important inherited risk factors for type 1 diabetes
(T1D) although also polymorphisms outside the HLA region modulate the predisposition to T1D. This
study set out to confirm a recent observation in which a novel expression quantitative trait locus was
formed by three single nucleotide polymorphisms (SNP) in the intron of HLA-DRA1 in DR3-DQ2 haplo-
types. The SNPs significantly increased the risk for T1D in DR3-DQ2 homozygous individuals and we
intended to further explore this association, in the Finnish population, by comparing two DR3-DQ2 pos-
itive genotypes. Cohorts with DR3-DQ2/DR3-DQ2 (N = 570) and DR3-DQ2/DR1-DQ5 (N = 1035) geno-
types were studied using TaqMan analysis that typed for rs3135394, rs9268645 and rs3129877. The
tri-SNP haplotype was significantly more common in cases than controls in the DR3-DQ2/DR3-DQ2
cohort (OR = 1.70 CI 95% = 1.15–2.51P = 0.007). However, no significant associations could be observed
in the DR3-DQ2/DR1-DQ5 cohort.
 2021 The Authors. Published by Elsevier Inc. on behalf of American Society for Histocompatibility and
Immunogenetics. This is an open access article under the CC BY license (http://creativecommons.org/
licenses/by/4.0/).1. Introduction
Type 1 diabetes (T1D) has a multifactorial etiology attributable
to genetic and environmental factors that affect the development
of islet autoimmunity and the progression of b-cell destruction.
The strongest observable T1D-susceptibility factors are polymor-
phisms in HLA class II genes, especially DRB1, DQA1 and DQB1
but also DPB1 [1,2]. Moreover, genetic variants of HLA class I alle-
les, including A*24, B*18, and B*39 are also associated with T1D [3].
Still, numerous poorly characterized polymorphisms in the HLA-
region have been found to modify T1D susceptibility [4]. >40 single
nucleotide polymorphisms (SNP) outside the HLA-region have
been associated with T1D. However, these SNPs have only a minoreffect on the disease risk, when compared to the strong effect of
HLA-DR/DQ susceptibility factors [5,6].
A recent study by Aydemir et al. described three novel SNP in
intron-1 of HLA-DRA1 which modulated the T1D-risk conferred
by DRB1*03-DQA1*05-DQB1*02 haplotypes in a mixed study
group consisting of European ancestry study subjects from the
Type 1 Diabetes Genetic Consortium (T1DG) and from a Swedish
cohort [7]. They suggested that the combined ‘‘tri-SNP” haplotype
functions as an expression quantitative trait locus (eQTL) signifi-
cantly increasing T1D susceptibility. The tri-SNP combination con-
sisting of three risk alleles (rs3135394-A, rs9268645-G, and
rs3129877-G) was significantly associated with T1D in both tri-
SNP heterozygotes and homozygotes.
This study aimed to further investigate the T1D-risk conferred
by the tri-SNP in a large Finnish cohort. In addition to studying
(DR3)-DQA1*05-DQB1*02 (DR3-DQ2) homozygotes, the most com-
L. Nygård, Antti-Pekka Laine, M. Kiviniemi et al. Human Immunology 82 (2021) 912–916mon heterozygous DR3-DQ2 genotype, DR3-DQ2/(DR1/10)-
DQB1*05:01 (DR1-DQ5) was selected for further study [8].
According to a DR/DQ risk estimation of trio families in the Fin-
nish Pediatric Diabetes Register (FPDR) is the DR3-DQ2/DR3-DQ2
genotype conferring a moderately increased risk (OR = 4.08 CI
95% = 2.49–6.69) while the DR3-DQ2/DR1-DQ5 genotype confers
only a slightly increased risk (OR = 1.42 CI 95% = 1.09–1.85) for
T1D [8]. We hypothesized that the tri-SNP could be used as an
additional risk factor when estimating T1D susceptibility in
prospective genetic screening.2. Materials and methods
2.1. Study population and cohorts
Samples from children with T1D were obtained from the FPDR
and the healthy controls were obtained from children screened
for eligibility in the Finnish Diabetes Prediction and Prevention
study (DIPP). Most pediatric units in Finland are participating in
the FPDR, and the sample library is perceived to represent the com-
plete population diversity of individuals with T1D [9]. The DIPP-
study recruits newborn infants for HLA-based genetic screening
in three university hospitals (Turku, Oulu, and Tampere) in South-
west, Middle and Northern Finland, screening approximately 25%
of all births annually [8].
In the DR3-DQ2/DR3-DQ2 cohort there were 190 T1D DNA sam-
ples obtained from the FPDR and 380 control samples from the
DIPP study. The controls had not developed islet specific autoanti-
bodies (IAA, GADA or IA-2A) or T1D during the follow-up. The DR3-
DQ2/DR1-DQ5 cohort included 384 DNA samples from children
diagnosed with T1D in the FPDR and 651 DIPP blood spot samples
from subjects who were screened for DQB1 but who were not eli-
gible for follow-up study. None of the controls have been diag-
nosed with T1D in the participating hospitals by the end of year
2017. The male to female sex ratio for the DR3-DQ2/DR3-DQ2
cohort was 64.7% and 35.3% in cases and 53.2% and 46.8% in con-
trols, respectively. Corresponding ratios in the DR3-DQ2/DR1-
DQ5 cohort was 51.7% and 48.3% in cases and 50.8% and 49.2% in
controls. This study was authorized by the ethics committees of
the participating hospitals in accordance with the Declaration of
Helsinki. All samples and data were collected with informed con-
sent from the legal guardians and stored according to the protocols
of the DIPP-study and the FPDR.2.2. HLA genotyping
HLA class II genotyping was tailored to define major haplotypes
associated with a risk for or protection against T1D. Typing was ini-
tiated with full-house typing for major DQB1 alleles, with four-
digit resolution, followed by a panel of probes defining three infor-
mative DQA1 alleles (DQA1*02:01, DQA1*03, DQA1*05) discrimi-
nating between major haplotypes containing DQB1*02,
DQB1*03:01 and DQB1*03:03 alleles. DRB1*04 alleles associated
with variable T1D-risk were further defined in DQB1*03:02 posi-
tive samples. The haplotypes are presented by their abbreviated
names, complemented by DR specificities (in parenthesis), which
were deduced from determined linkages in populations of Euro-
pean descent [10]. A set of DQB1 genotypes had their second exon
hypervariable region sequenced so that alternative genotypes
could be distinguished. The DQB1-assay is an in-house homoge-
neous assay using asymmetric PCR wherein the DQB1 gene is
amplified with lanthanide labelled probes and complementary
quencher oligonucleotides. Probes and quenchers hybridize after
amplification by cooling in room temperature followed by lan-
thanide measurement by time-resolved fluorometry [11].913The HLA-DRB1 assays and a part of the DQA1 assays were per-
formed using the DELFIA method [11,12]. DQA1 typing in recent
samples, including the blood spot samples with DQB1*02/
DQB1*05:01 genotypes, was performed using a homogeneous
end-point PCR assay with fluorescence resonance energy transfer
(FRET). The method is based on two non-luminescent oligonu-
cleotide probes, defining each allele: one carrying a non-
luminescent lanthanide chelate and the other carrying a light-
absorbing antenna ligand. Hybridization of probes to adjacent
positions on target DNA leads to the formation of a highly lumines-
cent lanthanide chelate complex by reporter molecule self-
assembly [13]. Four digit typing for DQA1*05 and DQB1*02 alleles
was not performed since the haplotype formed by them in popula-
tions with European ancestry invariably consists of DQA1*05:01
and DQB1*02:01 alleles whereas other common DQA1*05 alleles
DQA1*05:05 and DQA1*05:03 are found in haplotype with
DQB1*03:01 [14].2.3. Tri-SNP genotyping
DNA extraction from EDTA-blood was performed according to a
standard salting-out protocol [15]. DNA extraction from bloodspot-
cards was done by extraction and solution preparation according
to standard in-house protocol [11]. Undiluted stock samples and
samples extracted from EDTA blood with visible impurities were
purified with a NucleospinTM gDNA Clean-up kit (Macherey-Nagel,
ref. 740230.50) according to the manufacturers protocol. All DNA
concentrations were measured with a QubitTM 4 Fluorometer
(Thermo Fisher, cat. Q33226). The DR3-DQ2/DR1-DQ5 cohort
required additional HLA-typing due to lacking DQA1-data. DQA1-
typing was performed with homogenous asymmetric PCR using
lanthanide labelled oligonucleotide probes according to standard
in-house protocol [12]. Only DQA1*05-positive subjects were
included in the final DR3-DQ2/DR1-DQ5 cohort.
SNP genotyping was performed by TaqMan qPCR using on-the-
shelf TaqManTM probes (Thermo Fisher, cat. 4351379) for
rs3135394 (Assay ID: C__27466166_20), rs9268645 (Assay ID:
C__27466166_20) and rs3129877 (Assay ID: C__27466166_20).
The contents of the reaction solution were modified from the man-
ufacturers protocol to 2.5 ml TaqManTM Genotyping Master Mix
(Thermo Fisher, cat. 4371355), 0.06 ml of either 40x TaqManTM
probe, 1.44 ml MQ-water and 1 ml DNA (approx. 10 ng/ml). The
qPCR-reaction utilized a 96-well semi-skirted Framestar PCR-
plate (4titude, prod. 4ti-0770/C) with Framestar qPCR seals (4ti-
tude, prod. 4ti-0560). The qPCR was run on a QuantStudioTM 3
Real-Time PCR system (Thermo Fisher, cat. A28317) with a 96-
well 0.2 ml block. qPCR-amplification used preprogrammed set-
tings adjusted to a 10 ml reaction volume and to run for 50 cycles.
Reruns of undetermined samples used a 25% enlarged reaction vol-
ume with 2 ml DNA. Reruns of impure samples with observable
impurities used only 1 ml DNA. The genotyping results were ana-
lyzed with QuantStudioTM Designs & Analysis Desktop Software
(v1.5.1) with analytical call settings set at analyze Real-time Rn-
Median (Rna to Rnb). A summary of all calls intended for analysis
was made with Thermo Fishers ConnectTM cloud software for geno-
typing with previously specified call settings.2.4. Statistics
SNP frequencies were compared and P-values calculated using
Pearson Chi-square or Fisheŕs exact test when applicable. Linkage
disequilibrium values between respective tri-SNP components
were calculated using PLINK (v1.07) program [16] in DR3-DQ2
homozygote cohorts and using LDlink [17] in the Finnish excerpt
of 1000Genomes.
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Table 1 shows the frequency distribution of tri-SNP genotypes
in the DR3-DQ2/DR3-DQ2 cohort. GCA was the dominant haplo-
type and GCA homozygosity was the most common genotype with
a frequency of 75.8% in cases and 81.1% in controls. Homozygosity
for the T1D-associated AGG genotype was rare, although twice as
common in cases (5.3%) than controls (2.6%), albeit not signifi-
cantly different. The second most frequent genotype was AG-CG-
AG, an apparent combination of the AGG and GCA haplotypes,
which was more common in cases than in controls (P = 0.066).
Other genotypes were rare, only 4/190 (2.1%) in cases and
19/380 (5.0%) in controls had a combination different from GCA
or AGG. In the rare genotypes the AGG combination was present
as a probable genotype in one case and three controls whereas
the GCA combination was found in two cases and 12 controls
(Table 1). When the frequency of all cases with a possible AGG-
genotype 43/190 (22.6%) was compared to the controls 56/380
(14.8%) could a significant difference be detected (OR = 1.69 CI
95%= 1.09–2.63P = 0.019) (Table1).
When the three most common tri-SNP genotypes were ana-
lyzed independently, as done by Aydemir et al. [7], a trend with
considerable overlapping values could be observed (Table 1). The
frequency of children with a single or a double AGG haplotype
was significantly more common in cases (OR = 1.70 CI 95%=
1.15–2.51, P = 0.007) than in the controls. An analysis of the SNPs
allelic frequency distributions in the DR3-DQ2/DR3-DQ2 cohort
showed a significant increase in minor rs9268645-G (OR = 1.65
CI 95%= 1.13–2.42P = 0.010) and minor rs3129877-G (OR = 1.48
CI 95%= 1.03–2.13P = 0.034) amongst the cases (data not shown).
The minor rs3135394-A was more common in cases but showed
only a borderline significance (OR = 1.43 CI 95%= 0.99–2.06P = 0.
054).
No AGG homozygotes were present in the DR3-DQ2/DR1-DQ5
cohort leading to a strong dominance of GCA haplotypes (Table 2).Table 1
Summary of genotypes and haplotypes in the DR3-DQ2/DR3-DQ2 cohort. Genotype comb
rs3129877 respectively. Genotypes compare combinations resulting in a determined A-G-G
Haplotypic odds ratios and p-values are relative to the lower risk GCA/GCA haplotype. Odd
exact test when applicable.
DR3-DQ2/DR3-DQ2
Genotypes combinations Cases (%) Co
AA-GG-GG 10 (5.3) 10
AA-CG-GG 1 (0.5) 1 (
AA-CG-AG 2 (
AA-CC-AG 1 (
AG-CG-AG 32 (16.8) 43
AG-CG-AA 1 (
AG-CC-AG 1 (0.5) 6 (
AG-CC-AA 1 (0.5) 4 (
GG-CG-AG 1 (
GG-CC-GG 1 (0.5) 3 (




Other 147 (77.4) 32
Total N 190 38
Haplotype combinations Cases (%) Co
AGG/AGG 10 (5.4) 10
GCA/AGG* 32 (17.2) 43
GCA/GCA 144 (77.4) 30




GCA 320 (86.0) 65
Total N 372 72
*Deduced haplotypes in AG-CG-AG genotypes.
914However, the AG-CG-AG genotype (probable AGG/GCA) was
slightly more frequent in cases than in controls, albeit the differ-
ence was not significant. By comparing all cases with a possible
AGG-genotype 49/462 (10.6%) against the controls 48/573 (8.4%)
no significant difference could be detected (OR = 1.30 CI 95%= 0.8
5–1.97P = 0.221). Similarly, no significant differences in allelic dis-
tribution could be observed in the DR3-DQ2/DR1-DQ5 cohort (data
not shown).
Linkage disequilibrium (LD) values for respective SNPs were
analyzed in DR3-DQ2 homozygote cases and controls as well as
in the Finnish general population data retrieved from the 1000Gen-
omes collection [18]. LD-analysis of DR3-DQ2 SNP data using
PLINK (v1.07) found a strong LD between all SNPs (D’> 0.9) and
allele frequencies were in strong correlation (r2 > 0.8), demonstrat-
ing that the tri-SNP components are inherited together and sel-
domly recombined (Table 3). A strong LD between all SNPs
(D’=1) was also found in the 1000Genomes dataset but the allele
frequencies were noticeably disproportionate and only a weak cor-
relation was found between them (r2 = 0.02–0.22), indicating that
the tri-SNP components are inherited from several different haplo-
types (Table 4). This is also demonstrated by the fact that the
minor allele frequencies of respective SNP (rs3135394,
rs9268645, rs3129877) in the DR3-DQ2 cohort (0.11, 0.089, 0.11)
clearly deviate from the Finnish general populations minor allele
frequencies (0.084, 0.29, 0.41), according to data obtained from
the Genome Aggregation Database (gnomAD) [19].4. Discussion
This study verified that the tri-SNP in the intron of HLA-DR3
gene of DR3-DQ2 haplotype has a significant effect on the risk
for T1D development as first reported in 2019 [7]. The association
was detectable in Finnish DR3-DQ2/DR3-DQ2 homozygotes, where
the AGG-haplotype conferred an increased risk for T1D. The asso-
ciation followed a similar pattern to the original study, in whichinations are arranged in the order of minor to major SNP, rs3135394, rs9268645 and
genotype in comparison to other genotypes without a complete A-G-G combination.
s ratios and P-values were calculated using Pearson Chi-square, P-values with Fisher’s
ntrols (%) OR (95% CI) P-value










8 (81.1) 0.73 (0.48–1.11) 0.144
(14.8) 1.69 (1.09–2.63) 0.019
4 (85.7) 0.59 (0.38–0.92) 0.019
0
ntrols (%) OR (95% CI) P-value
(2.8) 2.14 (0.87–5.25) 0.090
(11.9) 1.59 (0.97–2.62) 0.066
8 (85.3) 1.00 (NA) NA
1
(8.7) 1.70 (1.15–2.51) 0.007
9 (91.3) 1.00 (NA) NA
2
Table 2
Summary of genotypes and haplotypes in the DR3-DQ2/DR1-DQ5 cohort. Genotype combinations are arranged in the order of minor to major SNP, rs3135394, rs9268645 and
rs3129877 respectively. Genotypes compare combinations resulting in a determined A-G-G genotype in comparison to other genotypes without a complete A-G-G combination.
Haplotypic odds ratios and p-values are relative to the lower risk GCA/GCA haplotype. Odds ratios and P-values were calculated using Pearson Chi-square, P-values with Fisher’s
exact test when applicable.
DR3-DQ2/DR1-DQ5
Genotype combinations Cases (%) Controls (%) OR (95% CI) P-value
AG-GG-GG 1 (0.2)
AG-CG-GG 1 (0.2) 1 (0.2)





GG-CG-AG 4 (0.9) 1 (0.2)
GG-CC-AG 4 (0.9) 11 (1.9)
GG-CC-AA 404 (87.4) 508 (88.7) 0.89 (0.61–1.30) 0.550
Genotypes
A-G-G
49 (10.6) 48 (8.4) 1.30 (0.95–1.97) 0.221
Other 413 (77.2) 525 (91.6) 0.77 (0.51–1.17) 0.221
Total N 462 573
Haplotype combinations Cases (%) Controls (%) OR (95% CI) P-value
AGG/AGG
GCA/AGG* 47 (10.4) 47 (8.5) 1.26 (0.82–1.92) 0.291
GCA/GCA 404 (89.6) 508 (91.5) 1.00 (NA) NA
Total N 451 555
Haplotypes
AGG
47 (5.2) 47 (4.2) 1.24 (0.82–1.88) 0.302
GCA 855 (94.8) 1063 (95.8) 1.00 (NA) NA
Total N 902 1110
*Deduced haplotypes in AG-CG-AG genotypes.
Table 3
Linkage disequilibrium between analyzed SNPs in the DR3-DQ2/DR3-DQ2. Respective
case and control dataset LD-value is presented in the case/control field. The whole-
cohort LD-value was calculated with frequency data from both the case and the
control dataset. The summarized LD-result is presented below the case/control value.
LD-values were calculated with PLINK.
DR3-DQ2/DR3-DQ2
r2 rs3135394 rs9268645 rs3129877
rs3135394 1/1 0.938/0.786 0.939/0.803
rs9268645 0.938/0.786 1/1 0.918/0.796
rs3129877 0.939/0.803 0.918/0.796 1/1
D0 rs3135394 rs9268645 rs3129877
rs3135394 1/1 1/0.983 0.979/0.902
rs9268645 1/0.983 1/1 1/0.983
rs3129877 0.939/0.803 0.918/0.796 1/1
Table 4
Linkage disequilibrium between tri-SNPs alleles in a 1000Genomes excerpt. Values
were retrieved from the 1000Genomes Finnish population data collection using
LDlink.
1000Genomes
r2 rs3135394 rs9268645 rs3129877
rs3135394 1 0.023 0.103
rs9268645 0.023 1 0.225
rs3129877 0.103 0.225 1
D0 rs3135394 rs9268645 rs3129877
rs3135394 1 1 1
rs9268645 1 1 1
rs3129877 1 1 1
L. Nygård, Antti-Pekka Laine, M. Kiviniemi et al. Human Immunology 82 (2021) 912–916the AGG-heterozygote formed an intermediate risk group and the
AGG-homozygote a higher risk group. No significant associations
were found in the DR3-DQ2/DR1-DQ5 cohort. However, the
insignificant results of reported allele, genotype, and haplotype fre-
quencies resulted in odds ratios with a direction similar to those in
the DR3-DQ2/DR3-DQ2 cohort. Moreover, LD-analysis of the three915SNPs presented a strong LD (D’> 9), which was to be expected since
the tri-SNP components are residing within a 100 bp region. How-
ever, the strong difference in correlation coefficients values, when
comparing r2-values provided by the 1000Genomes dataset
(r2 = 0.02–0.22) with the DR3-DQ2 dataset (r2 > 0.8), would suggest
that the SNPs are in a moderate LD with the DR3-DQ2 haplotype.
A limitation of this study is that all tri-SNP haplotypes cannot
be deductively determined based on our method of SNP-typing.
This limitation includes AG-CG-AG (AGG/GCA), which was the sec-
ond most common genotype in the study of Aydemir et al. [7]. The
DR3-DQ2 relation to AGG/GCA in the DR3-DQ2/DR1-DQ5 cohort
cannot be determined without sequencing. However, the domi-
nance of GCA homozygotes in both cohorts and the rare presence
of AGG combinations in other genotypes, besides AG-CG-AG,
deductively suggest that the AG-CG-AG genotype can be inter-
preted as the heterozygous AGG/GCA genotype.
Based on a 1000 genome data analysis Aydemir and coworkers
suggested that the tri-SNP affects HLA-DQB1 allele expression as
an eQTL, a function which might explain the increased T1D-risk
[7]. Specific alleles associated with T1D in both DRB1 and DQB1
loci have been found to encode molecules able to present islet anti-
gen derived peptides to T lymphocytes [20] and an incrased
expression detected of these HLA molecules in antigen presenting
cells [21] could also enhance this antigen presentation.
However, neither that report nor this study have considered
allele specificity in other loci within the studied haplotypes, like
HLA-DP, class I HLA loci or other HLA-polymorphisms. The DR3-
DQ2 haplotype conferred risk has been found to be dependent on
factors outside the DR/DQ loci including the HLA-DP loci [2]. Fur-
thermore, HLA-B18 positive DR3-DQ2 haplotypes have been
observed to be more susceptible to T1D than B8 positive haplo-
types [22]. Several other polymorphisms as SNPs in DMB and
DOB genes, andmicrosatellite locus TNFc have also been associated
with T1D; demonstrating risk effects which are independent of
DRB1, DQA1 and DQB1 [23].
L. Nygård, Antti-Pekka Laine, M. Kiviniemi et al. Human Immunology 82 (2021) 912–916It should be noted that the frequency of risk-associated tri-SNP
haplotypes in our population of DR3-DQ2 homozygous children
with T1D (14%) was clearly lower than the 30.9% described
amongst Swedish cases in the earlier study [7]. When compared
to many other European populations is the HLA-diversity in Fin-
land quite low. This is an issue when studying T1D-related risk fac-
tors that could be restricted to rare HLA-haplotypes and are
accordingly hard to identify in large numbers. For example, the
DR3-DQ2 haplotype usually carries the lower risk B8 allele and
very rarely the high-risk associated B18 allele [24,25]. The low fre-
quency of high-risk associated DR3-DQ2 haplotypes, carrying the
DR3-DQ2 restricted tri-SNP, reduce the practicability of tri-SNP
inclusion in future risk screening programs as the addition would
not significantly enhance the sensitivity and the specificity of the
genetic screening.
By eliminating HLA-heterogeneity we were able to detect the
tri-SNPs risk effect in a DR3-DQ2/DR3-DQ2 cohort, but not in the
DR3-DQ2/DR1-DQ5 cohort. The tri-SNP haplotype could be deduc-
tively determined in homozygous genotypes eliminating the need
for sequencing. However, HLA heterozygosity and the low fre-
quency of respective tri-SNPs minor allele in the DR3-DQ2/DR1-
DQ5 cohort reduced the applicability of the results. To conclude,
we demonstrated that the earlier reported tri-SNP haplotype, in
the intron of HLA-DRA1 of DR3-DQ2 haplotype, is significantly
associated with T1D risk in Finnish DR3-DQ2 homozygotes.
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